Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – The nonhuman animal is a model for human disease
Reexamination Certificate
2003-08-29
2009-12-29
Bertoglio, Valarie (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
The nonhuman animal is a model for human disease
C800S003000, C800S014000
Reexamination Certificate
active
07638678
ABSTRACT:
The present invention relates to an animal model for human perimenopause and menopause. Also provided by the present invention are methods of making the animal model and methods of screening using the model. Also provided are methods of inducing ovarian failure in animals such as pets and wildlife.
REFERENCES:
patent: 6107540 (2000-08-01), Sawyer et al.
patent: 6583334 (2003-06-01), Haslam
Acarturk, F and Robinson, Jr. Vaginal permeability and enzymatic activity studies in normal and ovariectomized rabbits, Pharmaceutical Research, 13:779-783, 1996.
Abel, TW et al., The effects of hormone replacement therapy on hypothalmic neuropeptide gene expression in a primate model of menopause. Jour Clin Endocrin Metab, 84:2111-2118, 1999.
Osei-Hiyaman, D et al, 1998, Amer Jour Epidemiology, 148:1055-1061.
Amant, C et al, 2001, Criculation, 104:2576-2581.
Mulholland, SG, 1982, Journal of Urology, 127:1010-1013.
B. J. Smith, et al., Reproductive Toxicology, vol. 5, No. 4, pp. 379-383, “Comparison of Random and Serial Sections in Assessment of Ovarian Toxicity”, 1991.
Written Opinion, Mar. 30. 2005.
Loretta P. Mayer, et al., “The foll cle-Deplete Mouse Ovary Produces Androgen”, Biology of Reproduction, vol. 71, No. 1, XP-002368701, Jul. 2004, pp. 130-138.
Miriam J.J. de Kleijn et al.; “Endogenous Estrogen Exposure and Cardivascular Mortality Risk in Postmenopausal Women”; American Journal of Epidemiology, vol. 155, No. 4, pp. 339-345; 2002.
Caren G. Solomon et al.: “Menstrual Cycle Irregularity and Risk for Future Cardivascular Disease”; The Journal of Clinical Endocrinology & Metabolism, 87(5), pp. 2013-2017; 2002.
Frank B. Hu, MD et al.; “Age at Natural Menopause and Risk of Cardivascular Disease”; Arch Intern Med/vol. 159, pp. 1061-1066; May 24, 1999.
Francine Grodstein et al; “A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prvention of Cardiovascular Disease”; Annals of Internal Medicine, vol. 133, No. 12; pp. 933-941; Dec. 19, 2000.
Francine Grodstein et al; “Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study”; Annals of Internal Medicine; vol. 135, No. 1, pp. 1-8; Jul. 3, 2001.
Frank B. Hu, MD et al.; “Postmenopausal Hormone Therapy and the Risk of Cardiovascular Disease: The Epidemiologic Evidence”; The American Journal of Cardiology; vol. 90(1A), pp. 26F-29F; Jul. 3, 2002.
NIH: Postmenopausal Hormone Therapy Information; http://www.nih.gov/PHTindex.htm; 4pp., Jul. 26, 2003.
Karin H. Humphries et al; “Risks and benefits of hormone replacement therapy: The evidence speaks”; Canadian Medical Association, 168(8), pp. 1001-1010; Apr. 15, 2003.
Gail A. Laughlin et al; “Hysterectomy, Oophorectomy, and Endogenous Sex Hormone Levels in Older Women: The Rancho Bernardo Study”; The Journal of Clinical Endocrinology & Metabolism; vol. 85, No. 2, pp. 645-651; 2000.
Manuel Neves-e-Castro et al; “Results from WHI and HERS II—Implications for Women and the prescriber of HRT”; Maturitas 42 (2002) 255-258.
Bjarne K. Jacobsen et al' “Age at Natural Menopause and All-Cause Mortality: A 37-Year Follow-up of 19/731 Norwegian Women”; American Journal of Epidemiology, vol. 157, No. 10, pp. 923-929; 2003.
Sally A. Shumaker, Ph.D. et al; “Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women The Women's Health Initiative Memory Study: A Randomized Controlled Trial”; JAMA, vol. 289, No. 20 (Reprinted), pp. 2651-2662; May 28, 2003.
Peter P. Zandi, Ph.D. et al.; “Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women The Cache County Study”; JAMA, vol. 288, No. 17, pp. 2123-2129; Nov. 6, 2002.
Susan M. Fontaine et al; “Stereochemical Aspects of Vinylcyclohene Bioactivation in Rodent Hepatic Microsomes and Purified Human Cytochrome P450 Enzyme Systems”; DMD, vol. 29, No. 2, pp. 179-184; 2001.
S.M. Borman et al; “Ovotoxicity in Female Fischer Rats and B6 Mice Induced by Low-Dose Exposure to Three Polycyclic Aromatic Hydrocarbons: Comparison through Calculation of an Ovotoxic Index”; Toxicology and Applied Pharmacolocy, vol. 167, pp. 191-198; 2000.
Patricia B Hoyer et al; “Ovarian Toxicity of 4-Vinylcyclohexene Diepoxide: A Mechanistic Model”; Toxicologic Pathology, vol. 29, No. 1, pp. 91-99; 2001.
Patricia B. Hoyer et al; “Assessment of Follicle Desruction in Chemical-Induced Ovarian Toxicity”; Annu. Rev. Pharmacol. Toxicol., vol. 36, pp. 307-331; 1996.
Loretta P. Mayer et al; “Long-term effects of ovarian follicular depletion in rats by 4-vinylcyclohexene diepoxide”; Reproductive Toxicology, vol. 16, pp. 775-781; 2002.
Stephen B. Hooser et al; “Long-Term Ovarian and Gonadotropin Changes in Mice Exposed to 4-Vinylcyclohexene”; Reproductive Toxicology, vol. 8, No. 4, pp. 315-323; 1994.
Bill J. Smith et al; “The Role of Epoxidation in 4-Vinylcyclohexene-Induced Ovarian Toxicity”; Toxicology and Applied Pharmacology, vol. 105, pp. 372-381; 1990.
L.N. Springer et al; “Involvement of Apoptosis in 4-Vinylcyclohexene Diepoxide-Induced Ovotoxicity in Rats1” Toxicology and Applied Pharmacology, vol. 139, pp. 394-401; 1996.
P.J. Devine et al; “Ultrastructural Evaluation of Oocytes During Atresia in Rat Ovarian Follicles1”; Biology of Reproduction, vol. 63, pp. 1245-1252; 2000.
Xiaming Hu et al; “Expression and Redistribution of Cellular Bad, Bax and Bc1-XLProtein Is Associated with VCD-Induced Ovotoxicity in Rats1” Biology of Reproduction, vol. 65, pp. 1489-1495; 2001.
Xiaoming Hu et al; “Apoptosis Induced in Rats by 4-Vinylcyclohexene Diepoxide is Associated with Activation of Caspase Cascades1”; Biology of Reporduction, vol. 65, pp. 87-93; 2001.
Xiaoming Hu et al; “Activation of Mitogen-Activated Protein Kinases and AP-1 Transcription Factor in Ovotoxicity Induced by 4-Vinylcyclohexene Diepoxide in Rats1”; Biology of Reproduction, vol. 67, pp. 718-724; 2002.
S.M. Borman et al; “Single Dose of the Ovotoxicant 4-Vinylcyclohexene Diepoxide Is Protective in Rat Primary Ovarian Follicles”; Toxicology and Applied Pharmacology, vol. 158, pp. 244-252; 1999.
Kary E. Tohmpson et al; “17β-Estradiol Affords Protection against 4-Vinylcyclohexene Diepoxide-Induced Ovarian Follicle Loss in Fischer-344 Rats”; Endocrinology, 143(3), pp. 1058-1065; Mar. 2002.
Lori Mosca, MD et al; “Cardiovascular Disease in Women A Statemtn for Healthcare Professionals From the American Heart Association”; Circulation, vol. 96, No. 7, pp. 2468-2482; Oct. 7, 1997.
Suzanne Oparil; Supplement to Hypertension; Arthur C. Corcoran Memorial Lecture; “Hormones and Vasoprotection”; Journal of the American Heart Association, vol. 33, No. 1, Part II; Jan. 1999.
Stephen Hulley, MD et al; “Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women”; JAMA, vol. 280, No. 7, pp. 605-613; Aug. 19, 1998.
Dr. Anderson et al; “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women”; JAMA, vol. 288, No. 3, pp. 321-333; Jul. 17, 2002.
David W. Purdie; “Consequences of long-term hormone replacement therapy”; British Medical Bulletin, vol. 56, No. 3, pp. 809-823; 2000.
Carmen Rodriguez, MD, MPH et al; “Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women”; JAMA, vol. 285, No. 11, pp. 1460-1465; Mar. 21, 2001.
Francis L. Bellino, Ph.D.; “Nonprimate Animal Models of Menopause: Workshop Report”; Menopause: The Journal of the North American Menopause Society, vol. 7, No. 1, pp. 14-24; 2000.
Howard L. Judd, MD; “Hormonal Dynamics Associated with the Menopause”; Clinical Obsterics an
Hoyer Patricia B.
Mayer Loretta P.
Bertoglio Valarie
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
The Arizona Board of Regents
LandOfFree
Animal model for perimenopause and menopause and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Animal model for perimenopause and menopause and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Animal model for perimenopause and menopause and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090916